Get access to our best features
Get access to our best features
Published 2 years ago

U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients

Summary by Ground News
Pfizer's Paxlovid is authorised to treat newly infected, at-risk people in order to prevent severe illness. More than 162,000 courses were dispensed last week - compared with an average of 33,000 a week since the drug was launched late last year. But higher use has also come with more reports from people who say their symptoms eased only to return a few days after finishing a five-day regimen.

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 50% of the sources lean Right
2024 US Election NewsEverything you need to know about 2024, including updates on candidates, news blindspots, and reliable coverage of the biggest issues.
Explore coverage
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)